BEDMINSTER, N.J., Dec. 15 /PRNewswire-FirstCall/ -- Bioject Medical
Technologies Inc. (Nasdaq: BJCT), a leading developer of needle-free drug
delivery systems, announced today that the Company has recently completed a
Phase I clinical study comparing its Iject(TM) pre-filled, needle-free drug
delivery system to the traditional needle-and-syringe.
The study was sponsored by Bioject and performed at an independent third
party Organization, Comprehensive Phase One, a division of Comprehensive
NeuroScience, Inc. The Phase I research facility, located in Fort Lauderdale,
Florida, was responsible for all aspects of the study including the final
report. Subcutaneous injections of 0.5 ml of Saline were administered to 60
healthy volunteers in the triceps, the abdomen, or the thigh. Each subject
received two injections, one with the standard needle-and syringe on one side
and an injection with the Iject(TM) on the opposite side. Subjects were then
asked to compare the needle-free injections to the needle-and-syringe
injections with regards to pain, tolerability and preference. Results from
this study indicated that the Iject(TM) pre-filled, needle-free injection
device was less painful than the needle and syringe, preferred by the
volunteers and easier-to-use than the needle-and-syringe. Data from this
study is expected to be presented at an upcoming medical conference and
published shortly in a peer review journal.
Dr. Maria Gutierrez, Principal Investigator conducting the study, stated,
"The Iject(TM) needle-free injection drug delivery system offers a significant
improvement in the way injectable medications are administered when compared
to the traditional needle-and-syringe. This method of administering
medications is preferred by volunteers and the clinical staff and will change
the standard of care for injection therapies, both at the clinics and for
patients administering self-injections at home."
Commenting on the study, Jim O'Shea, Chairman, President and CEO of
Bioject, noted, "We are very pleased with the results of this study and are
optimistic about the future success of the Iject(TM). Not only does this
offer the clinician a safer method of administering injections, it also offers
an alternative for individuals at home who must administer their own
medications and we are continuing to see increased interest from potential
partners for the Iject(TM)."
Bioject Medical Technologies Inc., based in Bedminster, New Jersey, with
operations in Portland, Oregon, is an innovative developer and manufacturer of
needle-free drug delivery systems and vial adapter products. Needle-free
injection works by forcing medication at high speed through a tiny orifice
held against the skin. This creates a fine stream of high-pressure fluid
penetrating the skin and depositing medication in the tissue beneath. The
Company is focused on developing mutually beneficial agreements with leading
pharmaceutical, biotechnology, and veterinary companies.
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995, including statements
regarding Bioject's expectations with respect to future revenues and earnings
and additional agreements with strategic partners. Such forward-looking
statements involve known and unknown risks, uncertainties and other factors
that may cause the actual results, performance or achievements of the Company,
or industry results, to be materially different from any future results,
performance, or achievements expressed or implied by such forward-looking
statements. Such risks, uncertainties and other factors include, without
limitation, the risk that the Company's products, including the cool.click(TM)
and the SeroJet(TM), will not be accepted by the market, the risk that the
Company will be unable to successfully develop and negotiate new strategic
relationships or maintain existing relationships, the risk that Bioject's
current or new strategic relationships will not develop into long-term revenue
producing relationships, the fact that Bioject's business has never been
profitable and may never be profitable, uncertainties related to Bioject's
dependence on the continued performance of strategic partners and technology,
uncertainties related to the time required for the Company to complete
research and development, obtain necessary clinical data and government
clearances, the risk that the Company may be unable to produce our products at
a unit cost necessary for the products to be competitive in the market and the
risk that the Company may be unable to comply with the extensive government
regulations applicable to Bioject's business. Readers of this press release
are referred to the Company's filings with the Securities and Exchange
Commission, including the Company's reports on Form 10-K and Forms 10-Q for
further discussions of factors that could affect the Company's business and
its future results. Forward-looking statements are based on the estimates and
opinions of management on the date the statements are made. The Company
assumes no obligation to update forward-looking statements if conditions or
management's estimates or opinions should change.
For more information about Bioject, visit: http://www.bioject.com.
SOURCE Bioject Medical Technologies Inc.
 back to top
Related links:
http://www.bioject.com
CONTACT:
Cecelia C. Heer, Investor Relations Manager
of Bioject Medical Technologies Inc., +1-908-470-2800, ext. 5103,
or cheer@bioject.com
|
